SOUTH SAN FRANCISCO, Calif., Feb. 01, 2024 Denali Therapeutics Inc. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier .
Toronto, ON (PRWEB) September 02, 2022 Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical
Search jobs 20-Apr-2021 Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
Half of All Patients With NSCLC Have Oncogene Mutations, Yet Many Patients Are Not Tested to Screen for Biomarkers
Professional Clinical Guidelines Recommend Broad Biomarker Testing for Actionable and Emerging Biomarkers, Including KRAS
Biomarker Assist™ May Provide Eligible Patients Savings on Biomarker Testing
Amgen (NASDAQ: AMGN) today announced the launch of Biomarker Assist™, a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist™, eligible patients may save on biomarker testing.